These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The burgeoning science of genetics and the impact on public policy. Hatch OG J Biolaw Bus; 2004; 7(4):3-6. PubMed ID: 15675088 [TBL] [Abstract][Full Text] [Related]
6. US officials urge biologists to vet publications for bioterror risk. Check E Nature; 2003 Jan; 421(6920):197. PubMed ID: 12529597 [No Abstract] [Full Text] [Related]
7. The threat of bioterrorism. Graham B; Talent J Disaster Med Public Health Prep; 2011 Sep; 5 Suppl 2():S170-1. PubMed ID: 21908693 [No Abstract] [Full Text] [Related]
8. The view from the top. Howard K Nature; 2003 Dec; 426(6967):696-7. PubMed ID: 14668873 [No Abstract] [Full Text] [Related]
9. US biodefense contracts continue to lure biotechs. Shaffer C Nat Biotechnol; 2010 Mar; 28(3):187-8. PubMed ID: 20212465 [No Abstract] [Full Text] [Related]
10. The patentability of antibodies in the United States. Lu DL; Collison AM; Kowalski TJ Nat Biotechnol; 2005 Sep; 23(9):1079-80. PubMed ID: 16151395 [TBL] [Abstract][Full Text] [Related]
11. Cost/success projections for US biodefense countermeasure development. Matheny J; Mair M; Smith B Nat Biotechnol; 2008 Sep; 26(9):981-3. PubMed ID: 18779804 [No Abstract] [Full Text] [Related]
12. Biotech as Bush bows out. Lorenzo A Nat Biotechnol; 2008 Jan; 26(1):15-8. PubMed ID: 18183006 [No Abstract] [Full Text] [Related]